Company record · updated August 5, 2026
Ring Therapeutics Inc: 7 valuation observations from SEC filings
Every row below names the filing it came from. Coverage for this company runs September 30, 2025 to March 31, 2026.
7observations
7source filings
7verified rows
2026-03-31most recent as-of date
Source rails for this company: N-PORT fund mark (7).
Reported by 3 filers: T. Rowe Price Health Sciences Fund, Inc., T. Rowe Price Health Sciences Portfolio, T. Rowe Price New Horizons Fund, Inc..
| As of | Measure | Value | Reported by | Tier | What the filing says | Accession |
|---|---|---|---|---|---|---|
| 2026-03-31 | price per share | 4.6 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 60135.8 / balance 13073.0 [pp] | 000109926326006593 |
| 2026-03-31 | price per share | 4.6 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 1341838.4 / balance 291704.0 [pp] | 000109926326006598 |
| 2025-12-31 | price per share | 4.6 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 60135.8 / balance 13073.0 [pp] | 000109926326002544 |
| 2025-12-31 | price per share | 4.6 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 1341838.4 / balance 291704.0 [pp] | 000109926326002549 |
| 2025-12-31 | price per share | 4.6 USD | T. Rowe Price New Horizons Fund, Inc. | VERIFIED | valUSD 1308690.8 / balance 284498.0 [pp] | 000109926326002508 |
| 2025-09-30 | price per share | 4.6 USD | T. Rowe Price Health Sciences Fund, Inc. | VERIFIED | valUSD 1341838.4 / balance 291704.0 [pp] | 000109926325003642 |
| 2025-09-30 | price per share | 4.6 USD | T. Rowe Price Health Sciences Portfolio | VERIFIED | valUSD 60135.8 / balance 13073.0 [pp] | 000109926325003637 |
Reading these figures
A fund mark is the filer's own fair-value estimate at a quarter end, not a transaction price, and two filers can reach different values for the same date. A charter round price is the issue price of that series at issuance. Neither is a current market price. The capabilities page states the full limits.